- Home
- AMPX vs VIGL Comparison
AMPX vs VIGL Comparison
Compare AMPX & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMPX
- VIGL
- Stock Information
- Founded
- AMPX 2008
- VIGL 2020
- Country
- AMPX United States
- VIGL United States
- Employees
- AMPX N/A
- VIGL N/A
- Industry
- AMPX Industrial Machinery/Components
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- AMPX Miscellaneous
- VIGL Health Care
- Exchange
- AMPX Nasdaq
- VIGL Nasdaq
- Market Cap
- AMPX 154.4M
- VIGL 141.5M
- IPO Year
- AMPX N/A
- VIGL 2022
- Fundamental
- Price
- AMPX $2.12
- VIGL $3.19
- Analyst Decision
- AMPX Strong Buy
- VIGL Buy
- Analyst Count
- AMPX 7
- VIGL 5
- Target Price
- AMPX $8.17
- VIGL $16.80
- AVG Volume (30 Days)
- AMPX 2.9M
- VIGL 54.2K
- Earning Date
- AMPX 11-07-2024
- VIGL 11-07-2024
- Dividend Yield
- AMPX N/A
- VIGL N/A
- EPS Growth
- AMPX N/A
- VIGL N/A
- EPS
- AMPX N/A
- VIGL N/A
- Revenue
- AMPX $17,480,000.00
- VIGL N/A
- Revenue This Year
- AMPX $65.92
- VIGL N/A
- Revenue Next Year
- AMPX $327.46
- VIGL N/A
- P/E Ratio
- AMPX N/A
- VIGL N/A
- Revenue Growth
- AMPX 196.22
- VIGL N/A
- 52 Week Low
- AMPX $0.61
- VIGL $2.47
- 52 Week High
- AMPX $6.02
- VIGL $6.06
- Technical
- Relative Strength Index (RSI)
- AMPX 63.66
- VIGL 34.61
- Support Level
- AMPX $1.18
- VIGL $3.52
- Resistance Level
- AMPX $2.72
- VIGL $3.75
- Average True Range (ATR)
- AMPX 0.29
- VIGL 0.20
- MACD
- AMPX 0.08
- VIGL -0.08
- Stochastic Oscillator
- AMPX 60.71
- VIGL 12.56
About AMPX Amprius Technologies Inc.
Amprius Technologies Inc is engaged in the production of silicon anodes for high energy density lithium-ion batteries. The company's batteries are used for existing and emerging aviation applications, including unmanned aerial systems, such as drones and high-altitude pseudo satellites. All of its revenues is geographically earned in the United States.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.